Avidity Biosciences, Inc. is a pharmaceutical company based in the United States of America with a risk rating score of 24.7, categorizing it as a medium risk investment. Specializing in biotechnology, Avidity Biosciences focus on developing innovative Antibody Oligonucleotide Conjugates therapies to address various serious diseases. Their flagship product, AOC 1001, specifically targets a rare monogenic muscle disease. With a strong focus on ESG principles, Avidity Biosciences is committed to promoting environmental sustainability, social responsibility, and good governance practices.